Rocket


Overview
Financials
News + Filings
Key Docs
Charts
Ownership
Insiders





All
All (ex-4s)
10-K
10-Q
8-K
3,4,5
Proxy
Prospectus
Other

Tags
Quarterly results
Appointed director
CC transcript
Inv. presentation
Director departure

Paratek Pharmaceuticals, Inc. (PRTK) Create: Alert

All | News | Filings
Date FiledTypeDescription
10/02/2023 15-12G Form 15-12G - Securities registration termination [Section 12(g)]:
08/22/2023 DEFA14A Form DEFA14A - Additional definitive proxy soliciting materials and Rule 14(a)(12) material:
08/22/2023 DEFA14A Form DEFA14A - Additional definitive proxy soliciting materials and Rule 14(a)(12) material:
08/18/2023 DEFA14A Form DEFA14A - Additional definitive proxy soliciting materials and Rule 14(a)(12) material:
08/16/2023 DEFA14A Form DEFA14A - Additional definitive proxy soliciting materials and Rule 14(a)(12) material:
08/14/2023 DEFA14A Form DEFA14A - Additional definitive proxy soliciting materials and Rule 14(a)(12) material:
08/03/2023 10-Q Quarterly Report for the period ended June 30, 2023
08/02/2023 DEFA14A Form DEFA14A - Additional definitive proxy soliciting materials and Rule 14(a)(12) material:
08/02/2023 DEFA14A Form DEFA14A - Additional definitive proxy soliciting materials and Rule 14(a)(12) material:
08/02/2023 DEFM14A Form DEFM14A - Definitive proxy statement relating to merger or acquisition:
07/28/2023 SC 13E3/A Form SC 13E3/A - Going private transaction by certain issuers: [Amend]
07/28/2023 PRER14A Form PRER14A - Preliminary Proxy Soliciting materials:
07/11/2023 DEFA14A Form DEFA14A - Additional definitive proxy soliciting materials and Rule 14(a)(12) material:
07/11/2023 8-K Submission of Matters to a Vote of Security Holders  Interactive Data
06/30/2023 SC 13E3 Form SC 13E3 - Going private transaction by certain issuers:
06/30/2023 PREM14A Form PREM14A - Preliminary proxy statements relating to merger or acquisition:
06/07/2023 DEFA14A Form DEFA14A - Additional definitive proxy soliciting materials and Rule 14(a)(12) material:
06/07/2023 8-K Acquisition/merger/asset purchase announced
Docs: "UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549",
"Agreement and Plan of Merger, by and among the Company, Resistance Acquisition, Inc. and Resistance Merger Sub, Inc",
"Form of Contingent Value Rights Agreement to be entered into between Resistance Acquisition, Inc. and a Rights Agent",
"Form of Voting Agreement to be entered into between Parent and the Management Stockholders",
"Paratek Pharmaceuticals to be Acquired by Gurnet Point Capital and Novo Holdings"
06/06/2023 DEFA14A Form DEFA14A - Additional definitive proxy soliciting materials and Rule 14(a)(12) material:
06/06/2023 DEFA14A Form DEFA14A - Additional definitive proxy soliciting materials and Rule 14(a)(12) material:
06/06/2023 DEFA14A Form DEFA14A - Additional definitive proxy soliciting materials and Rule 14(a)(12) material:
06/06/2023 DEFA14A Form DEFA14A - Additional definitive proxy soliciting materials and Rule 14(a)(12) material:
05/18/2023 EFFECT Form EFFECT - Notice of Effectiveness:
05/09/2023 S-3 Form S-3 - Registration statement under Securities Act of 1933:
05/09/2023 10-Q Quarterly Report for the period ended March 31, 2023
04/27/2023 10-K/A Annual Report for the period ended December 31, 2022 [amend]
03/20/2023 SC 13G/A HIRSCHMAN ORIN reports a 4.9% stake in Paratek Pharmaceuticals, Inc.
03/17/2023 S-8 Form S-8 - Securities to be offered to employees in employee benefit plans:
03/16/2023 10-K Annual Report for the period ended December 31, 2022
03/14/2023 8-K Amendments to Articles of Incorporation or Bylaws; Change in Fiscal Year  Interactive Data
Docs: "EXHIBIT 3.1 AMENDED AND RESTATED BYLAWS OF PARATEK PHARMACEUTICALS, INC."
02/13/2023 SC 13G/A Form SC 13G/A - Statement of acquisition of beneficial ownership by individuals: [Amend]
01/20/2023 SC 13G/A NexPoint Real Estate Opportunities, LLC reports a 7% stake in Paratek Pharmaceuticals, Inc.
11/03/2022 10-Q Quarterly Report for the period ended September 30, 2022
08/03/2022 10-Q Quarterly Report for the period ended June 30, 2022
  Next >>

Rocket Data Systems, Inc. © 2019 | Contact Us | Data Disclaimer | Terms of Use | Privacy